Ruxolitinib Reduces JAK2 p.V617F Allele Burden in Patients With Polycythemia Vera Enrolled in the RESPONSE Study

Collectively, the data from this exploratory analysis suggest that ruxolitinib treatment for up to 4 years provides progressive reductions in JAK2 p.V617F allele burden in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.

 Ann Hematol

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.